In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis | Zendy

H. Van den Bossche | Zendy; G. Willemsens | Zendy; W Cools | Zendy; Frans W. Cornelissen | Zendy; W. Lauwers | Zendy; J.M. Van Cutsem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis

Author(s) -

H. Van den Bossche,

G. Willemsens,

W Cools,

Frans W. Cornelissen,

W. Lauwers,

J.M. Van Cutsem

Publication year - 1980

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.17.6.922

Subject(s) - ketoconazole , lanosterol , ergosterol , in vivo , candida albicans , sterol , mycelium , in vitro , pharmacology , drug , corpus albicans , biology , microbiology and biotechnology , chemistry , biochemistry , cholesterol , antifungal , botany

Ketoconazole, an orally active antimycotic drug, is a potent inhibitor of ergosterol biosynthesis in Candida albicans when added to culture media which support yeast or mycelial growth or to cultures containing outgrown mycelium. This inhibition coincides with accumulation of sterols with a methyl group at C-14 and can thus be attributed to an interference with one of the reactions involved in the removal of the 14 alpha-methyl group of lanosterol. When administered to rats infected with C. albicans, ketocanazole also inhibits fungal synthesis of ergosterol. A six-times-higher dose is required to effect cholesterol synthesis by rat liver.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research